TPWA
IMVT icon

Twin Peaks Wealth Advisors’s Immunovant IMVT Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$75 – 1171
2026
Q1 		$75 Buy
+3
New +$78 ﹤0.01% 2270
2025
Q3 		– Sell
-3
Closed -$46 – 1106
2025
Q2 		$46 Buy
+3
New +$45 ﹤0.01% 2197

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Twin Peaks Wealth Advisors's IMVT Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 3 shares — an estimated $75 sold.

Twin Peaks Wealth Advisors first reported a position in IMVT in Q2 2025 and held it in 2 quarters. The position peaked at $75 in Q1 2026. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 3 Immunovant shares in Q2 2026, an estimated $75.
  • Twin Peaks Wealth Advisors first reported a position in Immunovant in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Immunovant position peaked at $75 in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.